Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of pumitamig versus pembrolizumab as first-line monotherapy for PD-L1-high advanced or metastatic non-small cell lung cancer
CTR20261531Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pumitamig in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Apr 2026; status: active.
02
Drugs
pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261531.